These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10681089)

  • 21. Pharmacoeconomics of anti-epileptic drugs as adjunctive therapy for refractory epilepsy.
    Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):309-15. PubMed ID: 20545595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Epilepsy in adults: a costs-of-illness study].
    Vlasov PK; Orekhova NV; Filatova NV; Leonova MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3 Suppl 2):44-7. PubMed ID: 20873473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Quality of life and cost-effect aspects of epilepsy pharmacotherapy of women].
    Iutskova EV; Avakian GN; Tatarinova MIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(1):52-5. PubMed ID: 17310798
    [No Abstract]   [Full Text] [Related]  

  • 24. [Social and economic aspects of administration of new antiepileptic drugs].
    Dławichowska E; Owczarek K; Fiszer U
    Neurol Neurochir Pol; 2001; 35(2):245-52. PubMed ID: 11599223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurologist adherence to clinical practice guidelines and costs in patients with newly diagnosed and chronic epilepsy in Germany.
    Strzelczyk A; Bergmann A; Biermann V; Braune S; Dieterle L; Forth B; Kortland LM; Lang M; Peckmann T; Schöffski O; Sigel KO; Rosenow F
    Epilepsy Behav; 2016 Nov; 64(Pt A):75-82. PubMed ID: 27732920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy.
    Ettinger AB; Manjunath R; Candrilli SD; Davis KL
    Epilepsy Behav; 2009 Feb; 14(2):324-9. PubMed ID: 19028602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy.
    Heaney DC; Sander JW
    Neurology; 1999 Aug; 53(3):657-8. PubMed ID: 10449148
    [No Abstract]   [Full Text] [Related]  

  • 28. Following the money in epilepsy therapeutics.
    Boylan LS
    Clin Pharmacol Ther; 2010 Dec; 88(6):763; author reply 763-4. PubMed ID: 20927085
    [No Abstract]   [Full Text] [Related]  

  • 29. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues.
    Crawford P; Feely M; Guberman A; Kramer G
    Seizure; 2006 Apr; 15(3):165-76. PubMed ID: 16504545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New drugs for the treatment of epilepsy: a practical approach.
    Chowdhury D
    J Assoc Physicians India; 2013 Aug; 61(8 Suppl):19-39. PubMed ID: 24818327
    [No Abstract]   [Full Text] [Related]  

  • 31. Use and costs of concomitant medicines in epileptic patients in Poland: a 12-month prospective multicentre study.
    Majkowska-Zwolińska B; Jędrzejczak J; Majkowski J
    Seizure; 2011 Nov; 20(9):673-8. PubMed ID: 21757378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New antiepileptic drugs: should all be made available?
    Hachinski V
    Arch Neurol; 2000 Feb; 57(2):275. PubMed ID: 10681091
    [No Abstract]   [Full Text] [Related]  

  • 33. [Economic aspects of drug-resistant epilepsy].
    Owczarek K; Jedrzejczak J
    Neurol Neurochir Pol; 2001; 35(2):309-18. PubMed ID: 11599228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany.
    Strzelczyk A; Haag A; Reese JP; Nickolay T; Oertel WH; Dodel R; Knake S; Rosenow F; Hamer HM
    Epilepsy Behav; 2013 Jun; 27(3):433-8. PubMed ID: 23591262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of reimbursement restrictions on the choice of antiepileptic drugs: Belgian Study on Epilepsy Treatment (BESET).
    Boon P; Dejonghe P; Legros B; Sadzot B; van Rijckevorsel K; Schmedding E
    Seizure; 2008 Jun; 17(4):350-7. PubMed ID: 18203628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An overview of antiepileptic drug therapy.
    Cloyd JC
    Am J Hosp Pharm; 1993 Dec; 50(12 Suppl 5):S3-S4. PubMed ID: 8122699
    [No Abstract]   [Full Text] [Related]  

  • 37. [The costs of epilepsy in Germany].
    Dodel R; Rosenow F; Hamer HM
    Pharm Unserer Zeit; 2007; 36(4):298-305. PubMed ID: 17623320
    [No Abstract]   [Full Text] [Related]  

  • 38. The importance of botanical treatments in traditional societies and challenges in developing countries.
    Kakooza-Mwesige A
    Epilepsy Behav; 2015 Nov; 52(Pt B):297-307. PubMed ID: 26293314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Restrictions on the availability of antiepileptic drugs.
    Bergen DC
    Arch Neurol; 2000 Feb; 57(2):273-4. PubMed ID: 10681090
    [No Abstract]   [Full Text] [Related]  

  • 40. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 - A ten-year overview.
    Willems LM; Richter S; Watermann N; Bauer S; Klein KM; Reese JP; Schöffski O; Hamer HM; Knake S; Rosenow F; Strzelczyk A
    Epilepsy Behav; 2018 Jun; 83():28-35. PubMed ID: 29649671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.